Cargando…
Retinoblastoma in a 23-year-old adult treated with primary intra-arterial and intravitreal chemotherapy
Intra-arterial chemotherapy (IAC) continues to provide a globe-sparing alternative as primary treatment for retinoblastoma with few adverse events. While there is growing evidence to highlight the utility of IAC in children with retinoblastoma, adult cases treated with primary IAC have not previousl...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6561044/ https://www.ncbi.nlm.nih.gov/pubmed/31198299 http://dx.doi.org/10.4103/ojo.OJO_162_2018 |
_version_ | 1783426078628380672 |
---|---|
author | McMahon, Jeffrey F. Jabbour, Pascal Shields, Carol L. |
author_facet | McMahon, Jeffrey F. Jabbour, Pascal Shields, Carol L. |
author_sort | McMahon, Jeffrey F. |
collection | PubMed |
description | Intra-arterial chemotherapy (IAC) continues to provide a globe-sparing alternative as primary treatment for retinoblastoma with few adverse events. While there is growing evidence to highlight the utility of IAC in children with retinoblastoma, adult cases treated with primary IAC have not previously been characterized. We describe a rare case of Group D retinoblastoma in a 23-year-old adult treated successfully with IAC and intravitreal chemotherapy. This is a retrospective case report of a single patient. Subsequent to IAC and intravitreal chemotherapeutic treatments, at last follow-up 14 months following initial presentation and 8 months since last treatment, the retinoblastoma demonstrated complete regression into a partially calcified scar, with complete resolution of intravitreal and subretinal seeds and no evidence of tumor recurrence. Visual acuity improved to 20/30 in the left eye. There were no adverse events from therapy. Despite its rarity, it is important to consider retinoblastoma in the differential diagnosis of a white mass, even in an adult. Furthermore, this case highlights the utility of IAC for retinoblastoma, despite older patient age. |
format | Online Article Text |
id | pubmed-6561044 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Wolters Kluwer - Medknow |
record_format | MEDLINE/PubMed |
spelling | pubmed-65610442019-06-13 Retinoblastoma in a 23-year-old adult treated with primary intra-arterial and intravitreal chemotherapy McMahon, Jeffrey F. Jabbour, Pascal Shields, Carol L. Oman J Ophthalmol Case Report Intra-arterial chemotherapy (IAC) continues to provide a globe-sparing alternative as primary treatment for retinoblastoma with few adverse events. While there is growing evidence to highlight the utility of IAC in children with retinoblastoma, adult cases treated with primary IAC have not previously been characterized. We describe a rare case of Group D retinoblastoma in a 23-year-old adult treated successfully with IAC and intravitreal chemotherapy. This is a retrospective case report of a single patient. Subsequent to IAC and intravitreal chemotherapeutic treatments, at last follow-up 14 months following initial presentation and 8 months since last treatment, the retinoblastoma demonstrated complete regression into a partially calcified scar, with complete resolution of intravitreal and subretinal seeds and no evidence of tumor recurrence. Visual acuity improved to 20/30 in the left eye. There were no adverse events from therapy. Despite its rarity, it is important to consider retinoblastoma in the differential diagnosis of a white mass, even in an adult. Furthermore, this case highlights the utility of IAC for retinoblastoma, despite older patient age. Wolters Kluwer - Medknow 2019 /pmc/articles/PMC6561044/ /pubmed/31198299 http://dx.doi.org/10.4103/ojo.OJO_162_2018 Text en Copyright: © 2019 Oman Ophthalmic Society http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. |
spellingShingle | Case Report McMahon, Jeffrey F. Jabbour, Pascal Shields, Carol L. Retinoblastoma in a 23-year-old adult treated with primary intra-arterial and intravitreal chemotherapy |
title | Retinoblastoma in a 23-year-old adult treated with primary intra-arterial and intravitreal chemotherapy |
title_full | Retinoblastoma in a 23-year-old adult treated with primary intra-arterial and intravitreal chemotherapy |
title_fullStr | Retinoblastoma in a 23-year-old adult treated with primary intra-arterial and intravitreal chemotherapy |
title_full_unstemmed | Retinoblastoma in a 23-year-old adult treated with primary intra-arterial and intravitreal chemotherapy |
title_short | Retinoblastoma in a 23-year-old adult treated with primary intra-arterial and intravitreal chemotherapy |
title_sort | retinoblastoma in a 23-year-old adult treated with primary intra-arterial and intravitreal chemotherapy |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6561044/ https://www.ncbi.nlm.nih.gov/pubmed/31198299 http://dx.doi.org/10.4103/ojo.OJO_162_2018 |
work_keys_str_mv | AT mcmahonjeffreyf retinoblastomaina23yearoldadulttreatedwithprimaryintraarterialandintravitrealchemotherapy AT jabbourpascal retinoblastomaina23yearoldadulttreatedwithprimaryintraarterialandintravitrealchemotherapy AT shieldscaroll retinoblastomaina23yearoldadulttreatedwithprimaryintraarterialandintravitrealchemotherapy |